EVOlve your news

EvoBiotech published its last results on the use of extracellular vesicles derived from plants as a drug delivery system in the special issue “Extracellular Vesicles and Nucleic Acids in Health and Disease” of Cells Journal. This work demonstrates the use of edible plant-derived extracellular vesicles to vehicle mRNA-based vaccines for SARS-CoV-2 using an easy-to-use formulation […]

EU Startup.news is a popular website covering news about the European startup landscape and pointing-out the most promising startups for investment opportunities. We are pleased to share that EvoBiotech has been cited as one of the 15 innovative Italian Startups that are revolutionizing biotechnology in Italy. According to EU Startup.news, EvoBiotech is a cutting-edge biotech […]

EvoBiotech participated to the Annual Meeting of International Society for Extracellular Vesicles (International ISEV 2023) in Seattle to present its last results on the innovative use of plant extracellular vesicles as a delivery platform for mRNA-based vaccines.

Submission Acknowledgement Receipt PROF. GIOVANNI CAMUSSI PRESENTS EVOBIOTECH’S WORK, WATCH THE TALK! Submission Acknowledgement Receipt PROF. GIOVANNI CAMUSSI PRESENTS EVOBIOTECH’S WORK, WATCH THE TALK! On May 1-2, 2023 took place the ERCC19, the 19th Investigators’ Meeting of the Extracellular RNA Communication Consortium (ERCC). The ERCC is an NIH Common Fund program launched in 2013 to […]

EvoBiotech is proud to announce its latest publication on the use of extracellular vesicles derived from plants as a drug delivery system in the special issue “Advances of Membrane Vesicles in Drug Delivery Systems” of Pharmaceutics Journal. This work demonstrates the use of edible plant-derived extracellular vesicles to vehicle mRNA-based vaccines for SARS-CoV-2 using intramuscular, […]

An Opinion paper entitled “Plant-Derived Extracellular Vesicles as a Platform for Drug Delivery” was just published in Innovations in Tissue Engineering & Regenerative Medicine. The publication describes the advantages of plant-derived extracellular vesicles as carriers and their relevance for the future of drug delivery. The complete article at the link: https://crimsonpublishers.com/iterm/pdf/ITERM.000523.pdf

Evobiotech received the recognition for the successful completion of the incubation program 2019-2022 of Incubatore d’Imprese 2i3T. Three years of growth and activities that brought the company to develop multiple therapeutic platforms using plant-derived extracellular vesicles.

Turin, November 14th 2022 EvoBiotech S.r.l. announces the appointment of Mr. Marco Dieci as member of the Board and Chief Operating Officer. EvoBiotech is a Biotech company developing a novel technology platform using plant-derived Extracellular Vesicles (EV) aimed at improving the healing efficacy of advanced dressings and medications used in wound care treatments and at […]

EvoBiotech, an innovative start-up operating in the biotechnology sector, announces the entry into the share capital of Nocturnal Labs SpA, an Operational Holding Company with a strong innovative vision, and of LuMar. The “seed” investment for a total of € 1 million to EvoBiotech is intended for the development of a project on extracellular vesicles […]